Back to search

Aristotle University Of Thessaloniki (AUTH)

Κυτταρική θεραπεία οξείας και χρόνιας ηπατικής βλάβης με χορήγηση κυττάρων μυελού των οστών ή με κινητοποιητές αιμοποιητικών στελεχιαίων κυττάρων

Abstract

dc:description

The recognized potential of bone marrow (BM) cells to differentiate into a broad spectrum of tissues has emerged intense research interest on their use as possible candidates for cell therapy of acute and chronic liver diseases. Ιt has been reported that bone marrow could serve as a source of cells facilitating liver repopulation in case of hepatic damage both in experimental and clinical studies as well. The aim of the present thesis was to explore the effect of two bone marrow subpopulations, mesenchymal (MSCs) and hematopoietic (HSCs) stem cells in experimental animal models of acute and chronic liver injury. MSCs, MSCs-secreted molecules and their combination, proved effective in ameliorating liver fibrosis by inhibiting the proliferation of myofibroblasts, increasing VEGF concentration and restoring a functional liver vasculature. These effects were accompanied by a change in the expression pattern of proinflammatory cytokines in cirrhotic animals which received treatment.In contrast, MSCs administration in induced acute liver injury did not improve liver’s histology, regardless of the route of administration and the number of infused cells. This may be related to the highly inflammatory microenvironment in acute liver failure, which seems to adversely affect the efficiency of MSCs. In order to investigate HSCs contribution to the restoration of chronic liver injury in CCl4-treated mice, we comparatively tested G-CSF, the most widely used mobilizing agent, Plerixafor, a novel mobilizing agent of HSCs, as well as their combination. Either single-agent mobilization or the combination of agents significantly ameliorated hepatic damage by decreasing fibrosis and restoring the abnormal vascular network in the liver of mobilized mice as compared to CCl4-only mice. The combination of G-CSF+Plerixafor yielded significantly higher numbers of circulating HSCs over other groups, however, the degree of fibrosis reduction was similar among all mobilized mice. The liver homing potential of HSCs differed among the various mobilization approaches. An extended G-CSF treatment provided the highest anti-fibrotic effect of all tested modalities, inducing proliferation of hepatic stem cells and decreasing the hepatic inflammation. Plerixafor, despite the reduced liver homing potential of Plerixafor-mobilized HSCs, reversed fibrosis mainly by increasing hepatic PPAR-γ and VEGF expression. In all groups, BM-derived mature hepatocytes as well as liver-committed BM stem cells were detected only at low frequencies in the liver, implying that the hepatic recovery is regulated by alternative mechanisms, largely independent of the frequency of HSCs in the liver. It is possible that the mobilizing agents per se, exert a direct, non-HSC-dependent, hepatotrofic effect to the liver, contributing independently from or/and in parallel with the HSCs to hepatic reconstitution.Conclusively, the results of this doctoral thesis suggest that both MSCs and their secreted molecules, as well as HSCs mobilization agents, G-CSF, Plerixafor and G-CSF+Plerixafor, provide potent anti-fibrotic effects and contribute to the reconstruction and regeneration of liver parenchyma by acting differentially during the wound healing process.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsolaki, Eleftheria
  • Τσολάκη, Ελευθερία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37324

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsolaki, Eleftheria; Τσολάκη, Ελευθερία. Κυτταρική θεραπεία οξείας και χρόνιας ηπατικής βλάβης με χορήγηση κυττάρων μυελού των οστών ή με κινητοποιητές αιμοποιητικών στελεχιαίων κυττάρων. Aristotle University Of Thessaloniki (AUTH), 2014. http://hdl.handle.net/10442/hedi/37324